• LAST PRICE
    8.5300
  • TODAY'S CHANGE (%)
    Trending Down-0.0400 (-0.4667%)
  • Bid / Lots
    8.1000/ 7
  • Ask / Lots
    8.9800/ 9
  • Open / Previous Close
    8.5300 / 8.5700
  • Day Range
    Low 8.5300
    High 8.5300
  • 52 Week Range
    Low 4.8500
    High 19.6600
  • Volume
    1,052

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 8.57
TimeVolumeURGN
09:32 ET9468.53
Data delayed at least 15 minutes.
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesURGN
Urogen Pharma Ltd
194.5M
-1.7x
---
United StatesMREO
Mereo Biopharma Group PLC
150.9M
-0.2x
---
United StatesWVE
WAVE Life Sciences Ltd
206.4M
-1.2x
---
United StatesXERS
Xeris Biopharma Holdings Inc
226.3M
-1.2x
---
United StatesGRTS
Gritstone bio Inc
249.7M
-2.5x
---
United StatesFIXX
Homology Medicines Inc
170.4M
-42.1x
---
As of 2022-08-08

Company Information

UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).

Contact Information

Headquarters
9 Ha'ta'asiya StRA'ANANA, Israel 4365007
Phone
---
Fax
---

Executives

Independent Chairman of the Board
Arie Belldegrun
President, Chief Executive Officer, Director
Elizabeth Barrett
Chief Financial Officer
Dong Kim
Chief Compliance Officer, General Counsel, Corporate Secretary
Jason Smith
Chief Medical Officer
Mark Schoenberg

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$194.5M
Revenue (TTM)
$54.1M
Shares Outstanding
22.7M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.92
EPS
$-5.05
Book Value
$0.37
P/E Ratio
-1.7x
Price/Sales (TTM)
3.6
Price/Cash Flow (TTM)
---
Operating Margin
-162.85%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.